Results 41 to 50 of about 1,662 (181)

Subconjunctival bevacizumab injection versus mitomycin C application after primary pterygium surgery

Delta Journal of Ophthalmology, 2019
Purpose The aim of this study was to compare subconjunctival bevacizumab injection and mitomycin C (MMC) application after primary pterygium surgery in terms of recurrence rates and complications.
Hani A Albialy, Haitham Y Al-Nashar
doaj   +1 more source

Topical Povidone Iodine 2.5% Versus 5% for Endophthalmitis Prophylaxis During Intravitreal Injections. [PDF]

J Ophthalmol
Purpose Topical povidone iodine (PI) has been shown to reduce the risk of endophthalmitis following intravitreal injections (IVIs). However, PI is a known ocular irritant and can result in significant eye discomfort. Currently, 5% PI is the most used concentration for ocular surface disinfection prior to IVI. 2.5% PI has been proposed as an alternative
Ajlan RS, Dalla S, Parikh RJ, Pfannenstiel MM, Champion MT, Rahman MA, Diaz FJ.   +6 more
europepmc   +2 more sources

Effects of Subconjunctival Bevacizumab Injection after Primary Pterygium Surgery

Journal of the Korean Ophthalmological Society, 2023
Purpose: This study evaluated the efficacy and safety of subconjunctival bevacizumab injection after primary pterygium surgery.Methods: We performed a conjunctivo-limbal autograft after pterygium resection in 136 eyes of 128 patients with primary pterygium between December 2019 and July 2021.
Eunyu Yoon, Minji Park, Jaewon Choi
openaire   +1 more source

Subconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium [PDF]

Journal of Clinical & Experimental Ophthalmology, 2013
Objective: To determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium.Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium.
openaire   +1 more source

Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium

Journal of Taibah University Medical Sciences, 2022
الملخص: أهداف البحث: الظفرة هي كتلة العين الخارجية الليفية الوعائية التي تنمو من الملتحمة إلى القرنية. لم يتم التحقيق في تأثير الحقن تحت الملتحمة لتريامسينولون وبيفاسيزوماب بشكل كاف في جميع أنحاء العالم.
Purnamanita Syawal, PhD, Budu Budu, PhD, Mochammad Hatta, PhD, Muhammad Nasrum Massi, PhD, Andi Muhammad Ichsan, PhD, Rahmawati Minhajat, PhD   +5 more
doaj   +1 more source

Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma [PDF]

International Journal of Ophthalmology, 2019
AIM: To compare the effectiveness of postoperative adjunctive use of subconjunctival bevacizumab in altering the outcome of primary trabeculectomy in terms of sustained lowering of intraocular pressure (IOP) and reduction of postoperative bleb ...
Sana’ Muhsen, Javiera Compan, Tze Lai, Christoph Kranemann, Catherine Birt   +4 more
doaj   +1 more source

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab

Case Reports in Ophthalmology, 2020
Corneal neovascularization (CNV) has a variety of causes and threatens corneal clarity, thus optimal visual acuity. Conventional medical management includes topical steroids and matrix metalloproteinase inhibitors like doxycycline.
Anna Krystyna Britton, Basil Bamford Crayford   +1 more
doaj   +1 more source

Bevacizumab as adjuvant therapy in the management of pterygium: a systematic review and Meta-analysis [PDF]

International Journal of Ophthalmology, 2017
AIM: To evaluate the clinical effect of bevacizumab in pterygium treatment. METHODS: A systematic review and quantitative Meta-analysis was performed. PubMed, EMBASE, Web of Science and Cochrane database were searched for eligible literatures published ...
Jian Liu, Jie-Hui Xu, Wen Xu, Guan-Lu Liang, Ji-Xian Lou, Yi Wang, Ji-Quan Wen, Yong-Bao Cao   +7 more
doaj   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, Volume 4, Issue 1, March 2026.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.

PLoS ONE, 2014
PurposeTo evaluate the effects and underlying mechanisms of early and late subconjunctival injection of bevacizumab on the inhibition of corneal neovascularization (NV).MethodsCorneal NV was induced by closed eye contact lens wear followed by a silk ...
Wei-Li Chen, Yan-Ming Chen, Hsiao-Sang Chu, Chung-Tien Lin, Lu-Ping Chow, Chih-Ta Chen, Fung-Rong Hu   +6 more
doaj   +1 more source